Oric Pharmaceuticals Inc recorded a cumulative net loss of $-140 million during 12 month ending in the second quarter 2026. The Healthcare sector has seen employees of 269 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3863, from total ranking in previous quarter at 4459.
South San Francisco, Calif. and San Diego, Aug. 02, 2024 - ORIC Pharmaceuticals, a clinical-stage oncology company dedicated to developing innovative treatments that address mechanisms of therapeutic resistance, has recently announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants serve as a testament to ORIC s commitment to attracting and retaining top talent within the competitive field of oncology research. On August 1, 2024, ORIC granted a total of 33,000 non-qualified stock options and 5,600 restricted stock units to two new non-executive employees who recently joined the company in July of the same year. This move follows earlier inducement grants made by ORIC Pharmaceuticals on October 2, 2023. These grants included 72,120 non-qualified stock options and 12,040 restricted stock units, awarded to four non-executive employees who had joined ORIC in September 2023.
ORIC Pharmaceuticals Secures $125 Million in Private Placement Financing and Reinforces Workforce with Inducement Grants, Reinforcing Commitment to Oncology Breakthroughs In a bid to strengthen its position in the field of oncology research and development, ORIC Pharmaceuticals has recently announced significant milestones. The clinical stage oncology company has successfully raised $125 million through a private placement financing round, drawing support from both new and existing investors. Additionally, the company has reinforced its workforce by granting inducement options and restricted stock units to several new non-executive employees. The private placement financing round, which generated considerable interest among investors, saw participation from prominent names in the financial industry. Entities such as Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech were among the investors contributing to this funding round. The substantial capital infusion is expected to fuel ORIC Pharmaceuticals continued efforts to develop innovative and effective treatments for therapeutic resistance in cancer patients.
Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
